Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Poseida Therapeutics Inc. PSTX

Healthcare Biotechnology
Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with a high unmet medical need. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumours.

The Power Play by The Market Herald
{{currentVideo.videoCaption}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (NDAQ:PSTX)

Fundamentals Snapshot (NDAQ:PSTX)

Current News (NDAQ:PSTX)

Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2022

PR Newswire March 9, 2023

Poseida Therapeutics Appoints Five New Members to Its Gene Therapy Scientific Advisory Board

PR Newswire March 1, 2023

Poseida Therapeutics Hosts Third Annual Virtual R&D Day Highlighting Novel Pipeline Assets and Latest Technology Innovations

PR Newswire February 22, 2023

Poseida Therapeutics to Present at H.C. Wainwright Cell Therapy Virtual Conference

PR Newswire February 14, 2023

Poseida Therapeutics to Host Third Annual Virtual R&D Day on February 22, 2023

PR Newswire February 8, 2023

Poseida Therapeutics Announces Board Change

PR Newswire January 31, 2023

Poseida Therapeutics Presents Preclinical Data from P-FVIII-101 Gene Therapy for Hemophilia A at the 64th ASH Annual Meeting & Exposition

PR Newswire December 11, 2022

Poseida Therapeutics to Present Early Data from Phase 1 Trials of P-MUC1C-ALLO1 and P-BCMA-ALLO1 at ESMO Immuno-Oncology 2022 Annual Congress

PR Newswire December 6, 2022

Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2022

PR Newswire November 10, 2022
View More News ››

Opinion & Analysis (NDAQ:PSTX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:PSTX)

Upcoming CAR-T Summit

Stock seems to be up they are presenting a Late Breaking abstract at upcoming CAR-T summit. Anyone know anything else about this one?
askretka - August 30, 2021
View more Bullboard ››

Infinity Stone Ventures Corp.

Infinity Stone Ventures Corp.

Infinity Stone Ventures Corp is engaged in the development of battery metals projects to fuel the green revolution, alongside ...
View More »